LEXINGTON, Mass. & NEW ORLEANS--(BUSINESS WIRE)--GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced results from two ongoing studies of its EndoBarrier™ Gastrointestinal Liner. One study evaluated the EndoBarrier as a treatment in patients who are obese and living with type 2 diabetes and the second study evaluated the EndoBarrier in patients who are obese. Notably, in the diabetes study at week 24 (n=16), the change in HbA1c was -1.5±0.4% while 58% of the subjects (n=7/12 with data) achieved HbA1c of 7% or less. These data were presented by Alex Escalona, M.D., Department of Digestive Surgery, Pontificia Universidad Católica de Chile, Santiago, Chile at Digestive Disease Week (DDW) 2010 in New Orleans, La.
